text.skipToContent text.skipToNavigation
Need help? Please contact us

Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 1 Million

Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 1 Million

Catalog #: 4Y-101C
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 1 million cells
Compare

 1’563.00 CHF
EA

Product Overview

Mobilized peripheral blood CD34+ hematopoietic stem and progenitor cells are positively selected using a immunomagnetic CD34 microbead labeling system. Cells are cryopreserved in Lonza Cryo Media in a cryovial. Cell purity is determined post thaw using a FACS assay. Count and viability is determined using AO/PI. Cells are collected from healthy donors following IRB protocols

Manufactured by AllCells®

Request More Info

Benefits

  • Obtain large quantities of CD34+ from a donor
  • Certificate of analysis (CoA) provided for each lot purchased
  • Test negative for mycoplasma, bacteria, yeast, and fungi
  • HIV-1, Hepatitis B and Hepatitis C are not detected for all donors and/or cell lots

Applications

  • CAR-T therapy development
  • iPSC generation
  • Autoimmune disease
  • Immunology
  • Cancer research

Storage and Content

  • 1 x Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood containing ≥ 1 million cells
Return to Top

SDS, CoA, and Instructions

Certificate of Analysis (CoA)

Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.

Return to Top

Educational Material

Brochures, White Papers etc.

  • Blood and Immune Cells

    Fueling your next discovery with unmatched cell and donor variety
  • Instructions and Technical Sheet- Human CD34+ Cells

  • CD34+ Cells for Cell and Gene Therapy Process Development

    In this interview Dr. Manon Destalminil, Bioprocessing Project Leader at CellProthera, discusses the advantages of using research-grade CD34+ cells for cell and gene therapy process development. Please register to read.
Return to Top